Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106159158 | 10615915 | 8 | F | 201407 | 20160825 | 20141201 | 20160902 | EXP | PHHY2014CA092977 | SANDOZ | 66.96 | YR | M | Y | 0.00000 | 20160902 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106159158 | 10615915 | 1 | SS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | 100 UG, TID (10 DAYS POST 1ST) | 0 | 100 | UG | TID | |||||||
| 106159158 | 10615915 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, QMO (EVERY 4 WEEKS) | 0 | 60 | MG | /month | |||||||
| 106159158 | 10615915 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, (EVERY 24 DAYS) | 0 | 60 | MG | ||||||||
| 106159158 | 10615915 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, (EVERY 21 DAYS) | 0 | 60 | MG | ||||||||
| 106159158 | 10615915 | 5 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QD | Y | 0 | 10 | MG | QD | ||||||
| 106159158 | 10615915 | 6 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QOD (EVERY TWO DAYS) | Y | 0 | 10 | MG | |||||||
| 106159158 | 10615915 | 7 | PS | METOPROLOL. | METOPROLOL | 1 | Oral | 150 MG, BID | U | 73288 | 150 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 106159158 | 10615915 | 1 | Carcinoid tumour |
| 106159158 | 10615915 | 2 | Carcinoid tumour |
| 106159158 | 10615915 | 5 | Carcinoid tumour |
| 106159158 | 10615915 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 106159158 | 10615915 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 106159158 | 10615915 | Abdominal pain | |
| 106159158 | 10615915 | Acne | |
| 106159158 | 10615915 | Asthenia | |
| 106159158 | 10615915 | Blood pressure diastolic decreased | |
| 106159158 | 10615915 | Blood pressure systolic increased | |
| 106159158 | 10615915 | Body temperature decreased | |
| 106159158 | 10615915 | Carcinoid crisis | |
| 106159158 | 10615915 | Diarrhoea | |
| 106159158 | 10615915 | Frequent bowel movements | |
| 106159158 | 10615915 | Heart rate decreased | |
| 106159158 | 10615915 | Inappropriate schedule of drug administration | |
| 106159158 | 10615915 | Injection site bruising | |
| 106159158 | 10615915 | Injection site pain | |
| 106159158 | 10615915 | Nervousness | |
| 106159158 | 10615915 | Oedema peripheral | |
| 106159158 | 10615915 | Oropharyngeal pain | |
| 106159158 | 10615915 | Pruritus | |
| 106159158 | 10615915 | Tremor | |
| 106159158 | 10615915 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 106159158 | 10615915 | 1 | 20140424 | 201405 | 0 | |
| 106159158 | 10615915 | 2 | 20140501 | 0 | ||
| 106159158 | 10615915 | 5 | 20140710 | 0 | ||
| 106159158 | 10615915 | 6 | 20140925 | 201509 | 0 |